Abstinence · cannabis dependence
Buspirone showed no clear difference in participants abstinent at end of treatment compared with placebo (low certainty).
1 finding from 1 review
Participants with at least some Side Effects · cannabis dependence
Buspirone showed no clear difference in participants experiencing adverse effects compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · cannabis dependence
Buspirone showed no clear difference in participants withdrawn due to adverse effects compared with placebo (low certainty).
1 finding from 1 review
Completion of scheduled treatment · cannabis dependence
Buspirone showed no clear difference in completion of scheduled treatment compared with placebo (low certainty).
1 finding from 1 review
Benzodiazepine discontinuation, end of intervention · adults who withdraw from chronic benzodiazepine use
Buspirone showed no clear difference in benzodiazepine discontinuation, end of intervention compared with placebo (low certainty).
1 finding from 1 review
Benzodiazepine discontinuation, longest · adults who withdraw from chronic benzodiazepine use
Buspirone showed no clear difference in benzodiazepine discontinuation, longest compared with placebo (low certainty).
1 finding from 1 review
Benzodiazepine withdrawal symptoms, end of intervention · adults who withdraw from chronic benzodiazepine use
1 finding from 1 review
Benzodiazepine withdrawal symptoms, longest · adults who withdraw from chronic benzodiazepine use
1 finding from 1 review
Short‐term (1 week) percentage change (improvement) in overall speech production · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Short‐term (within 1 month) change in isolated movement, objective and subjective measures of speech production Cooper 2008 reported 3 speech measures: ICARS speech subscale. Scale from: 0 to 8. Higher scores indicate greater clinical severity Syl... · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
no estimate extracted
19 participants
Low
Short‐term (within 1 month) change in quality of life scores related to communication as measured by validated communication assessments · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Adverse effects (during study) · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
no estimate extracted
19 participants
GRADE not reported
Longer‐term burdens (minimum 1 month) (for example, demands on caregivers, frequency of tests, restrictions on lifestyle) · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Economic outcomes · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Tardive dyskinesia: No clinically important improvement · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia
ANXIOLYTIC ‐ BUSPIRONE may leads to lower tardive dyskinesia: No clinically important improvement compared with PLACEBO (low certainty).
1 finding from 1 review
Tardive dyskinesia: Deterioration of symptoms ‐ not reported · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects ‐ not reported · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether ANXIOLYTIC ‐ BUSPIRONE changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).
1 finding from 1 review
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found